Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.

Fiche publication


Date publication

septembre 2022

Journal

Frontiers in cardiovascular medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Pr PIVOT Xavier, Dr CURTIT Elsa, Dr MANSI Laura, Dr VERNEREY Dewi, Dr MOUGIN-GUILLAUME Fabienne, Dr JACQUINOT Quentin, Mr FALCOZ Antoine


Tous les auteurs :
Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F

Résumé

Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective supportive therapy in the management of side effects, but the cardioprotective effects of exercise are still unclear.

Mots clés

HER2 overexpression, breast cancer, cardiotoxicity, prevention, supervised exercise program, supportive care

Référence

Front Cardiovasc Med. 2022 09 23;9:1000846